Literature DB >> 6957025

Assessment of the specificity of human Ia alloantisera and alloantigens by the use of radioiodinated human Ia antigens.

N Tanigaki, R Tosi.   

Abstract

A method for preparing radiolabelled human Ia antigens and a utilization of the labelled antigens in defining the Ia specificity of antigens and antisera are presented. The standard preparation procedure involves solubilization with Renex 30 (a non-ionic detergent), purification by gel filtration and lectin-affinity chromatography, and radioiodination, and yields an Ia preparation with immunological purity of 48-62%. The basic procedure for defining the Ia specificity of antisera is a direct binding assay: it allows to react a given antiserum with a panel of labelled Ia preparations of different specificities and measures the extent of binding by the double antibody technique. The major or putatitve specificity can be deduced from the reaction pattern. The specificity can be further evaluated by a sequential binding test or a binding inhibition test. The Ia tissue typing is performed by the binding inhibition assay: it measures the ability of test tissues to inhibit the binding of a reference labelled Ia preparation with a reference Ia antiserum. This assay permits Ia typing with unseparated blood leukocytes of 2 to 3 x 10(5). These radioimmunoassay procedures can offer a solution to problems involved in human Ia serology.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6957025     DOI: 10.1111/j.1399-0039.1982.tb00324.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  13 in total

1.  Serological discrimination of DR4 haplotypes by radioimmunoassay.

Authors:  N Tanigaki; R Tosi; G B Ferrara
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Southern blot and microfingerprinting analysis of two DR7 haplotypes.

Authors:  G Angelini; N Tanigaki; R Tosi; G B Ferrara
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

3.  Subset analysis of human class II molecules controlled by the DR2/Dw2 haplotype: two separate DR subsets carry the DR2 specificity.

Authors:  N Tanigaki; R Tosi; G B Ferrara
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

4.  Serological recognition of HLA-DR allodeterminant corresponding to DNA sequence involved in gene conversion.

Authors:  C C Berte; N Tanigaki; R Tosi; J Gorski; B Mach
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

5.  Radioimmunoassay typing gives a more precise definition of the HLA association of type 1 (insulin-dependent) diabetes.

Authors:  R Tosi; M Vela; D Adorno; A Longo; F Papola; D Maccarone; D Centis; N Tanigaki; M P Raponi; A Candela
Journal:  Diabetologia       Date:  1986-07       Impact factor: 10.122

6.  Isolation from human chronic-lymphocytic-leukaemia cells of membrane glycoproteins associated with Fc-receptor functions. Physical parameters and production of polyclonal antibodies.

Authors:  G Gorini; G A Medgyesi; M Garavini; K J Dorrington; J Down
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

7.  Immunochemistry of the HLA class II molecules isolated from a mouse cell transfected with DQ alpha and beta genes from a DR4 haplotype.

Authors:  N Tanigaki; R Tosi; J L Strominger; J Cooper
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

8.  Arg74 in HLA-DRB1 and DRB3 controls a DR3-related epitope.

Authors:  R Sorrentino; C Iannicola; S Costanzi; G Ratti; C Hurley; R Tosi; N Tanigaki
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

9.  Differential effects of gamma interferon on expression of HLA class II molecules controlled by the DR and DC loci.

Authors:  F Ameglio; M R Capobianchi; A Dolei; R Tosi
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

10.  Sheep lymphocyte antigens (OLA). II. Major histocompatibility complex class II molecules.

Authors:  N K Puri; C R Mackay; M R Brandon
Journal:  Immunology       Date:  1985-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.